This site uses cookies to collect activity data and personalize content. By continuing to navigate this site, you agree to allow us to collect information using cookies. Learn more about how we care for your data in our privacy notice.


DMPA-SC Evidence to Practice reports, resources, and references

By Reproductive Health

The DMPA-SC Evidence to Practice workshops in 2018 and 2019 have gathered together family planning experts, including ministry officials, partners, and donors from more than 20 countries.

Meeting participants met to develop country strategies for increasing voluntary access to subcutaneous DMPA (DMPA-SC)* within a wide range of contraceptive methods and to inform related policy decisions with current evidence. The reports and resources below summarize the plenaries, presentations, and discussions held to inform country planning. For more information, visit the DMPA-SC Access Collaborative page; sign up for our newsletter; or email

Meeting reports

Evidence and resource overviews

Effective delivery of DMPA-SC

Self-injection: Acceptability, feasibility, and effectiveness

*DMPA-SC: Subcutaneous depot medroxyprogesterone acetate.
Sayana Press is a registered trademark of Pfizer Inc. Uniject is a trademark of BD.

Read More